PAREXEL and Datavant Partner to Deliver Advanced Data and Real-World Evidence Analytics to Enhance Drug Development and Commercialization
Summary
BOSTON & SAN FRANCISCO--( BUSINESS WIRE )--PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, and Datavant, Inc., a healthcare technology company focused on enabling the secure de-identification and linking of healthcare datasets, today announced they are partnering to enhance clinical study design and operations, as well as the generation of real-world evidence.“Partnering with Datavant will allow PAREXEL to optimize clinical studies and real-world evidence generation using techniques that represent a true inflection point in how information will be consolidated in our industry.”Datavant’s technology offerings, coupled with PAREXEL’s wealth of expertise and years of experience in clinical study operations, real-world evidence generation, and working with multiple real-world data sources provide an opportunity to answer some of the most difficult questions in drug development and commercialization for the ultimate benefit of patients,” said Travis May, co-founder and CEO, Datavant.We simplify our clients’ journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services.PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world.